RUNX2 and chondrosarcoma: Although drug-sensitivity screening using a library of 334 compounds (Screening Committee of Anticancer Drugs [SCADS]) (47) failed to identify highly effective chemicals (Supplemental Table 6), modulations of histone deacetylase functions have been emphasized in fusion gene-positive sarcomas as well as the Runx2 pathway in chondrosarcoma (48, 49).